GlaxoSmithKline plc (LON:GSK) had its target price raised by Berenberg Bank from GBX 1,850 ($22.85) to GBX 1,890 ($23.34) in a research report released on Friday. They currently have a hold rating on the stock.
GSK has been the topic of several other research reports. BNP Paribas reissued an underperform rating and issued a GBX 1,520 ($18.77) target price on shares of GlaxoSmithKline plc in a report on Sunday, January 15th. JPMorgan Chase & Co. lowered their target price on GlaxoSmithKline plc from GBX 1,800 ($22.23) to GBX 1,600 ($19.76) and set a neutral rating on the stock in a report on Wednesday, January 4th. Shore Capital reissued a hold rating on shares of GlaxoSmithKline plc in a report on Friday, January 6th. Jefferies Group LLC upped their target price on GlaxoSmithKline plc from GBX 1,780 ($21.98) to GBX 1,800 ($22.23) and gave the company a buy rating in a report on Friday, February 17th. Finally, Beaufort Securities reissued a buy rating and issued a GBX 1,750 ($21.61) target price on shares of GlaxoSmithKline plc in a report on Thursday, February 16th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the stock. The company has an average rating of Hold and a consensus target price of GBX 1,744.73 ($21.55).
Shares of GlaxoSmithKline plc (LON:GSK) traded up 0.06% during mid-day trading on Friday, reaching GBX 1688.50. 4,929,658 shares of the company traded hands. GlaxoSmithKline plc has a 52-week low of GBX 1,363.00 and a 52-week high of GBX 1,745.56. The company’s 50 day moving average is GBX 1,619.43 and its 200 day moving average is GBX 1,593.30. The stock’s market capitalization is GBX 82.20 billion.
Your IP Address:
The company also recently disclosed a dividend, which will be paid on Thursday, April 13th. Stockholders of record on Thursday, February 23rd will be issued a GBX 23 ($0.28) dividend. This represents a dividend yield of 1.47%. This is an increase from GlaxoSmithKline plc’s previous dividend of $19.00. The ex-dividend date is Thursday, February 23rd.
In other news, insider Vivienne Cox acquired 342 shares of the business’s stock in a transaction dated Wednesday, February 8th. The shares were bought at an average cost of GBX 1,555 ($19.20) per share, for a total transaction of £5,318.10 ($6,567.99). Also, insider Moncef Slaoui acquired 56 shares of the business’s stock in a transaction dated Tuesday, March 7th. The stock was purchased at an average price of GBX 2,072 ($25.59) per share, for a total transaction of £1,160.32 ($1,433.02). Over the last 90 days, insiders bought 471 shares of company stock worth $786,697 and sold 52,038 shares worth $84,442,106.
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/glaxosmithkline-plc-gsk-given-new-gbx-1890-price-target-at-berenberg-bank/1709152.html
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.